Scott E. Smith
About
Scott E. Smith is a scholar working on Pathology and Forensic Medicine, Oncology and Hematology.
According to data from OpenAlex, Scott E. Smith has authored 113 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Pathology and Forensic Medicine, 36 papers in Oncology and 34 papers in Hematology. Recurrent topics in Scott E. Smith's work include Lymphoma Diagnosis and Treatment (42 papers), Chronic Lymphocytic Leukemia Research (19 papers) and Acute Myeloid Leukemia Research (16 papers). Scott E. Smith is often cited by papers focused on Lymphoma Diagnosis and Treatment (42 papers), Chronic Lymphocytic Leukemia Research (19 papers) and Acute Myeloid Leukemia Research (16 papers). Scott E. Smith collaborates with scholars based in United States, Germany and Canada. Scott E. Smith's co-authors include Simon N. Young, Robert O. Pihl, Frank R. Ervin, Ajay K. Gopal, Robert Chen, Anas Younes, Joseph D. Rosenblatt, Emily K. Larsen, Joseph M. Connors and Andreas Engert and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Journal of Clinical Oncology.
In The Last Decade
Scott E. Smith
109 papers receiving 4.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Scott E. Smith United States | 31 | 2.2k | 2.1k | 815 | 801 | 616 | 113 | 4.6k | ||
| Constance A. Griffin United States | 47 | 1.3k 0.6× | 3.2k 1.6× | 728 0.9× | 401 0.5× | 3.2k 5.2× | 140 | 8.8k | ||
| Neil Scolding United Kingdom | 52 | 2.4k 1.1× | 665 0.3× | 1.2k 1.5× | 1.7k 2.2× | 2.2k 3.5× | 218 | 7.9k | ||
| Guillermo Izquierdo Spain | 29 | 2.5k 1.1× | 698 0.3× | 140 0.2× | 911 1.1× | 1.4k 2.2× | 131 | 4.1k | ||
| Paola Cavalla Italy | 30 | 1.1k 0.5× | 468 0.2× | 658 0.8× | 844 1.1× | 996 1.6× | 83 | 3.1k | ||
| Daniel Wynn United States | 26 | 2.7k 1.2× | 1.0k 0.5× | 99 0.1× | 1.1k 1.4× | 342 0.6× | 50 | 3.6k | ||
| John Rose United States | 35 | 3.7k 1.7× | 986 0.5× | 104 0.1× | 1.8k 2.3× | 831 1.3× | 144 | 5.9k | ||
| Dusan Stefoski United States | 24 | 1.7k 0.8× | 592 0.3× | 138 0.2× | 641 0.8× | 386 0.6× | 56 | 2.7k | ||
| Christian Barro Switzerland | 34 | 3.2k 1.4× | 718 0.3× | 297 0.4× | 2.9k 3.7× | 1.8k 2.9× | 72 | 7.2k | ||
| Oluf Andersen Sweden | 39 | 2.6k 1.2× | 782 0.4× | 152 0.2× | 1.5k 1.8× | 2.0k 3.2× | 135 | 5.9k | ||
| Scott R. Plotkin United States | 48 | 845 0.4× | 1000 0.5× | 1.7k 2.0× | 4.1k 5.2× | 1.5k 2.4× | 216 | 7.8k |
Countries citing papers authored by Scott E. Smith
Since
Specialization
Citations
This map shows the geographic impact of Scott E. Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott E. Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott E. Smith more than expected).
Fields of papers citing papers by Scott E. Smith
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Scott E. Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott E. Smith. The network helps show where Scott E. Smith may publish in the future.
Co-authorship network of co-authors of Scott E. Smith
This figure shows the co-authorship network connecting the top 25 collaborators of Scott E. Smith. A scholar is included among the top collaborators of Scott E. Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott E. Smith. Scott E. Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Batchelor, Tracy T., Amy S. Ruppert, Susan M. Geyer, et al.. (2024). Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101. Blood Advances. 8(12). 3189–3199.
2.
Mumby, Patricia, William Adams, Scott E. Smith, Murali Rao, & Patrick J. Stiff. (2023). Pharmacotherapy for the Prevention of Depression and Behavioral Side Effects in Hematopoietic Stem Cell Transplantation Patients. Transplantation and Cellular Therapy. 30(3). 320.e1–320.e11.
3.
Ismail, Zahra, et al.. (2023). Impact of body mass index (BMI) and weight changes on hematopoietic stem cell transplant (HSCT) outcomes in the elderly population.. Journal of Clinical Oncology. 41(16_suppl). e19058–e19058.
4.
Bryan, Locke J., Carla Casulo, Pamela B. Allen, et al.. (2023). Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma. JAMA Oncology. 9(5). 683–683.
5.
Martin, Peter W., Sin‐Ho Jung, Brandelyn N. Pitcher, et al.. (2017). A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance). Annals of Oncology. 28(11). 2806–2812.
6.
Rodriguez, Tulio E., et al.. (2016). Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Biology of Blood and Marrow Transplantation. 22(8). 1391–1396.
7.
Bartlett, Nancy L., Robert Chen, Michelle A. Fanale, et al.. (2014). Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. Journal of Hematology & Oncology. 7(1). 24–24.
8.
Gopal, Ajay K., Nancy L. Bartlett, Andres Forero‐Torres, et al.. (2013). Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leukemia & lymphoma. 55(10). 2328–2334.
9.
Younes, Anas, Ajay K. Gopal, Scott E. Smith, et al.. (2012). Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma. Journal of Clinical Oncology. 30(18). 2183–2189.
10.
Jain, Nitin, Emily Curran, Neil M. Iyengar, et al.. (2012). Phase II study of the oral MEK inhibitor selumetinib (AZD6244) in advanced acute myeloid leukemia (AML).. Journal of Clinical Oncology. 30(15_suppl). 6582–6582.
11.
Choi, Sung Won, Patrick J. Stiff, Kenneth R. Cooke, et al.. (2012). TNF-Inhibition with Etanercept for Graft-versus-Host Disease Prevention in High-Risk HCT: Lower TNFR1 Levels Correlate with Better Outcomes. Biology of Blood and Marrow Transplantation. 18(10). 1525–1532.
12.
Evens, Andrew M., Irene Helenowski, Chadi Nabhan, et al.. (2011). Multicenter Analysis of Elderly Hodgkin Lymphoma (eHL): Outcomes and Prognostic Factors in the Modern Era. Blood. 118(21). 2625–2625.
13.
Nand, Sucha, John E. Godwin, Scott E. Smith, et al.. (2008). Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. Leukemia & lymphoma. 49(11). 2141–2147.
14.
Smith, Scott E., Amir A. Toor, Tulio E. Rodriguez, & Patrick J. Stiff. (2006). The administration of polymerized human hemoglobin (pyridoxylated) to a jehovah's witness after submyeloablative stem cell transplantation complicated by delayed graft failure. Comprehensive Therapy. 32(3). 172–175.
15.
Al‐Masri, Hytham, et al.. (2005). Megakaryoblastic leukemia with involvement of the pleural fluid. American Journal of Hematology. 79(3). 238–239.
16.
French, Margaret M., Scott E. Smith, Kamil Akanbi, et al.. (1999). Expression of the Heparan Sulfate Proteoglycan, Perlecan, during Mouse Embryogenesis and Perlecan Chondrogenic Activity In Vitro. The Journal of Cell Biology. 145(5). 1103–1115.
17.
Smith, Scott E., Margaret M. French, JoAnne Julian, et al.. (1997). Expression of Heparan Sulfate Proteoglycan (Perlecan) in the Mouse Blastocyst Is Regulated during Normal and Delayed Implantation. Developmental Biology. 184(1). 38–47.
18.
Godkin, James D., Scott E. Smith, Roger D. Johnson, & Jules J.E. Doré. (1997). The Role of Trophoblast Interferons in the Maintenance of Early Pregnancy in Ruminants. American Journal of Reproductive Immunology. 37(1). 137–143.
19.
Smith, Scott E., et al.. (1996). cDNA Cloning and Expression of HIP, a Novel Cell Surface Heparan Sulfate/Heparin-binding Protein of Human Uterine Epithelial Cells and Cell Lines. Journal of Biological Chemistry. 271(20). 11817–11823.
20.
Smith, Scott E., et al.. (1990). Ultrastructural morphometric analysis of the uterine epithelium during early pregnancy in the sheep. Reproduction. 89(2). 517–525.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Constance A. Griffin Breakdown of academic impact, for papers by Neil Scolding Breakdown of academic impact, for papers by Guillermo Izquierdo Breakdown of academic impact, for papers by Paola Cavalla Breakdown of academic impact, for papers by Daniel Wynn Breakdown of academic impact, for papers by John Rose Breakdown of academic impact, for papers by Dusan Stefoski Breakdown of academic impact, for papers by Christian Barro Breakdown of academic impact, for papers by Oluf Andersen Breakdown of academic impact, for papers by Scott R. Plotkin